Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
In spite of the clinical usefulness of cisplatin (CDDP), there are many occasions in which it is difficult to continue the administration of CDDP due to its nephrotoxicity and neurotoxicity. We examined the incorporation of CDDP into polymeric micelles to see if this allowed the resolution of these disadvantages. Cisplatin was incorporated into polymeric micelles through the polymer-metal complex formation between polyethylene glycol poly(glutamic acid) block copolymers and CDDP (NC-6004). The pharmacokinetics, pharmacodynamics, and toxicity studies of CDDP and NC-6004 were conducted in rats or mice. The particle size of NC-6004 was approximately 30 nm, with a narrow size distribution. In rats, the area under the curve and total body clearance values for NC-6004 were 65-fold and one-nineteenth the values for CDDP (P<0.001 and 0.01, respectively). In MKN-45-implanted mice, NC-6004 tended to show antitumour activity, which was comparable to or greater than that of CDDP. Histopathological and biochemical studies revealed that NC-6004 significantly inhibited the nephrotoxicity of CDDP. On the other hand, blood biochemistry revealed transient hepatotoxicity on day 7 after the administration of NC-6004. Furthermore, rats given CDDP showed a significant delay (P<0.05) in sensory nerve conduction velocity in their hind paws as compared with rats given NC-6004. Electron microscopy in rats given CDDP indicated the degeneration of the sciatic nerve, but these findings were not seen in rats given NC-6004. These results were presumably attributable to the significantly reduced accumulation of platinum in nerve tissue when NC-6004 was administered (P<0.05). NC-6004 preserved the antitumour activity of CDDP and reduced its nephrotoxicity and neurotoxicity, which would therefore seem to suggest that NC-6004 could allow the long-term administration of CDDP where caution against hepatic dysfunction must be exercised.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NC-6004 exhibited stable micelles in solution and slowly released cisplatin from the micelle for over 150 h in physiological saline. NC-6004 exhibited a narrow size distribution in solution with a size of 28 nm and loading of cisplatin in NC-6004 was up to 39% LC [153].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [153]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A similar polymeric micelle formulation where CDDP was coordinated with PEG-b-P(Glu) [153] evolved into a clinically evaluated polymeric micelle drug, NC-6004 which is described below in Section 5.3.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [153]
The cited source says what the claim attributes to it.
In the citing paper
“Originally developed by Kataoka’s group and NanoCarrier Co., Ltd., NC-6004 is a cisplatin-containing polymeric micelle formed via coordination of platinum drug with the P(Glu) segment of the PEG-b-P(Glu) block copolymer (PEG: 12,000 g/mol and P(Glu): 6,000 g/mol) [153].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [153]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Self-citationTumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Self-citationMaeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495 · cited 1×
“…polymers or nanoparticles, which are less prone to leak from intact vasculature, and which can be retained in solid tumour tissue for a longer time (enhanced permeability and retention effect (EPR) effect) (Matsumura and Maeda, 1986; Maeda and Matsumura, 1989; Maeda, 2000, 2001).”
BackgroundAmphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
Klibanov, A. L., Maruyama, K., Torchilin, V. P., & Huang, L. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)81016-h · Cited by 2,027 · cited 1×
“…93, 678 – 687 & 2005 Cancer Research UK All rights reserved 0007 – 0920/05 $30.00 www.bjcancer.com T ra n sla tio n a l T h e ra p e u tic s the reticuloendothelial system (RES) and to enhance the blood retention profile (Klibanov et al, 1990, 1991; Allen, 1994; Gabizon etal, 1996; Lasic, 1996).”
BackgroundInfluentialdu Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113 · cited 1×
“Consequently, these analogues are becoming the standard drugs for ovarian cancer (du Bois et al, 2003) and colon cancer (Cassidy et al, 2004).”
BackgroundNovel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice.
Nishiyama, N., Okazaki, S., Cabral, H., Miyamoto, M., Kato, Y., Sugiyama, Y., Nishio, K., Matsumura, Y., & Kataoka, K. (2003) · PubMed · Cited by 710
Self-citation(1998) · British Journal of Cancer · doi:10.1038/bjc.1998.1 · Cited by 654
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623 · cited 1×
“The Phase I clinical trial of adriamycin-incorporating polymeric micelles has been completed (Matsumura et al, 2004).”
BackgroundSelf-citationHamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602479 · Cited by 565
Self-citationCassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.069 · Cited by 525 · cited 1×
“Consequently, these analogues are becoming the standard drugs for ovarian cancer (du Bois et al, 2003) and colon cancer (Cassidy et al, 2004).”
Background
Cited by
Items 201–300 of 432
Mohammadabadi, A., Huynh, R. N., Wadajkar, A. S., Lapidus, R. G., Kim, A. J., Raub, C. B., & Frenkel, V. (2020) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ab9705 · Cited by 36
“Cisplatin-loaded polymeric micelles were also shown to reduce nephrotoxicity and neurotoxicity compared to the free drug (Uchino et al 2005).”
BackgroundPassive vs. Active Targeting: An Update of the EPR Role in Drug Delivery to Tumors
Upponi, J. R., & Torchilin, V. P. (2014) · Advances in delivery science and technology · doi:10.1007/978-3-319-08084-0_1 · Cited by 43
Huang, Y., He, Y., Huang, Z., Jiang, Y., Chu, W., Sun, X., Huang, L., & Zhao, C. (2017) · Nanoscale · doi:10.1039/c7nr02662e · Cited by 34
Syntheses of Macromolecular Ruthenium Compounds: A New Approach for the Search of Anticancer Drugs
Valente, A., & García, M. H. (2014) · Inorganics · doi:10.3390/inorganics2010096 · Cited by 34
Recent advances in polymeric core–shell nanocarriers for targeted delivery of chemotherapeutic drugs
Yang, X., & Xie, Y. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121094 · Cited by 33
Serras, A. S., Faustino, C. M. C., & Pinheiro, L. M. V. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081047 · Cited by 35
Wang, Z., Nogueira, L. P., Haugen, H. J., van der Geest, I. C. M., Rodrigues, P. C. D. A., Janssen, D. W., Bitter, T., van den Beucken, J. J. J. P., & Leeuwenburgh, S. C. G. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.12.023 · Cited by 42
Double-hydrophilic block copolymer–metal ion associations: Structures, properties and applications
Gineste, S., & Mingotaud, C. (2022) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2022.102808 · Cited by 33
“[49, 61] Various authors have also measured critical micelle concentration or aggregation,[72, 100, 115, 121, 125] even if the nature (frozen or dynamic) of the HPICs are unknown.”
BackgroundSeki, T., Fang, J. Q., & Maeda, H. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0131-6_3 · Cited by 36
Doi, T., Hamaguchi, T., Shitara, K., Iwasa, S., Shimada, Y., Harada, M., Naito, K., Hayashi, N., Masada, A., & Ohtsu, A. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3254-4 · Cited by 33
Nanoparticles use for Delivering Ursolic Acid in Cancer Therapy: A Scoping Review
Miatmoko, A., Mianing, E. A., Sari, R., & Hendradi, E. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.787226 · Cited by 34
“Cisplatin is an anticancer drug prepared with a polymeric micelle through the formation of a metal-polymer complex between cisplatin and poly-(ethylene glycol)-poly(glutamic acid) block copolymers (Nishiyama et al., 2003; Uchino et al., 2005).”
BackgroundYao, H., Shen, N., Ji, G., Huang, J., Sun, J., Wang, G., Tang, Z., & Chen, X. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c00478 · Cited by 32
EGFR Targeted Theranostic Nanoemulsion for Image-Guided Ovarian Cancer Therapy
Ganta, S., Singh, A., Kulkarni, P. P., Keeler, A. W., Piroyan, A., Sawant, R. R., Patel, N. R., Davis, B. J., Ferris, C. F., O’Neal, S., et al. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1660-z · Cited by 41
“However, their clinical use is still limited due to intrinsic and acquired resistance (4) and generalized toxicity, including acute nephrotoxicity, chronic neurotoxicity and adverse gastrointestinal reactions (5).”
BackgroundDai, Y., Wang, S., Shi, W., & Lang, M. (2017) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2017.08.011 · Cited by 33
“…side effects of chemotherapy (Ta & Proter, 2013; Zhao et al., 2016; Chen, Alberti, & Kalia, 2016; Hamaguchi et al., 2005; Matsumura et al., 2004; Uchino et al., 2005; El-Sherbiny & Smyth, 2010), and apatinib-encapsulated nanoparticles have been shown a promising effect on the prevention and…”
BackgroundVolovăț, S. R., Ciuleanu, T., Koralewski, P., Olson, J. E. G., Croitoru, A. E., Koynov, K. D., Stabile, S., Cerea, G., Osada, A., Bobe, I., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27684 · Cited by 32
“Here, combined NC-6004-gemcitabine therapy was well tolerated, as was the case in a Phase I/II study performed in Asia in pancreatic cancer patients (Study NC-6004-002) that demonstrated a toxicity profile similar to cisplatin [14].”
ResultLiu, M., Fu, J., Li, J., Wang, L., Tan, Q., Ren, X., Peng, Z., & Zeng, H. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.03.001 · Cited by 32
“Polymeric micelles have been applied in delivring many anticancer drugs such as cisplatin (Valery et al., 1999; chino et al., 2005), paclitaxel (Sung et al.”
BackgroundShikanov, A., Shikanov, S. A., Vaisman, B. L., Golenser, J., & Domb, A. J. (2011) · Chemotherapy Research and Practice · doi:10.1155/2011/175054 · Cited by 31
“As reported elsewhere [6], the plasma platinum levels after IV administration of free cisplatin were 11.”
BackgroundCross-linked Polymeric Micelles based on Block Ionomer Complexes
Kim, J. O., Ramasamy, T., Yong, C. S., Nukolov, N. V., Bronich, T. K., & Kabanov, A. V. (2013) · Mendeleev Communications · doi:10.1016/j.mencom.2013.07.001 · Cited by 30
Descriptive Inorganic Chemistry Researches of Metal Compounds
Akitsu, T. (2017) · InTech eBooks · doi:10.5772/65855 · Cited by 36
Synthesis and in vitro activity of ROMP-based polymer nanoparticles
Smith, D., Clark, S. H., Bertin, P. A., Mirkin, B. L., & Nguyen, S. T. (2009) · Journal of Materials Chemistry · doi:10.1039/b817511j · Cited by 31
Histological study on side effects and tumor targeting of a block copolymer micelle on rats
Kawaguchi, T., Honda, T., Nishihara, M., Yamamoto, T., & Yokoyama, M. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.02.011 · Cited by 33
Self-citationShi, H., van Steenbergen, M. J., Lou, B., Liu, Y., Hennink, W. E., & Kok, R. J. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119305 · Cited by 30
Sakai‐Kato, K., Un, K., Nanjo, K., Nishiyama, N., Kusuhara, H., Kataoka, K., Kawanishi, T., Goda, Y., & Okuda, H. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.027 · Cited by 31
Self-citationPolymeric micelles for pH-responsive delivery of cisplatin
Shahin, M., Nikouei, N. S., & Lavasanifar, A. (2014) · Journal of drug targeting · doi:10.3109/1061186x.2014.921925 · Cited by 31
“NC-6004 is based on PEO-poly(glutamic acid) (PEO-P(Glu)) block copolymers that form complex with CDDP and assemble to polymeric micelles [29,32,33].”
BackgroundZhou, H., Cooper, M. A., & Ziora, Z. M. (2016) · Biochemical Compounds · doi:10.7243/2052-9341-4-2 · Cited by 34
“6 times higher than that of cisplatin [86].”
BackgroundFolate-dactolisib conjugates for targeting tubular cells in polycystic kidneys
Shi, H., Leonhard, W. N., Sijbrandi, N. J., van Steenbergen, M. J., Fens, M. H. A. M., van den Dikkenberg, J. B., Toraño, J. S., Peters, D. J. M., Hennink, W. E., & Kok, R. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.11.019 · Cited by 31
Oukacine, F., Bernard, S., Bobe, I., & Cottet, H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.09.022 · Cited by 27
“The molar mass distribution of PEG-b-PGlu is generally characterized by size-exclusion chromatography [8,9] and the average polymerization degree of PGlu is obtained by (1)H NMR [8,9,13].”
Yokosawa, M., Sonoda, Y., Sugiyama, S., Saito, R., Yamashita, Y., Nishihara, M., Satoh, T., Kumabe, T., Yokoyama, M., & Tominaga, T. (2010) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.221.257 · Cited by 28
Polymeric Micelles for Formulation of Anti-Cancer Drugs
Lee, H., Soo, P. L., Liu, J., Butler, M., & Allen, C. J. (2006) · CRC Press eBooks · doi:10.1201/9781420006636-17 · Cited by 35
Wang, Q., Zhu, L., Li, G., Tu, C., Pang, Y., Jin, C., Zhu, B., Zhu, X., & Liu, Y. (2011) · Macromolecular Bioscience · doi:10.1002/mabi.201100186 · Cited by 26
Lee, D. Y., Kim, J. Y., Lee, Y., Lee, S., Miao, W., Kim, H. S., Min, J., & Jon, S. (2017) · Angewandte Chemie · doi:10.1002/ange.201707137 · Cited by 25
Moghaddas, S., Majmudar, P., Marín, R., Dezvareh, H., Qi, C., Soans, E., & Bose, R. N. (2012) · Inorganica Chimica Acta · doi:10.1016/j.ica.2012.05.040 · Cited by 28
Callari, M., de Souza, P. L., Rawal, A., & Stenzel, M. H. (2017) · Angewandte Chemie · doi:10.1002/ange.201701471 · Cited by 25
Liu, K., Xiang, J., Wang, G., Xu, H., Piao, Y., Liu, X., Tang, J., Shen, Y., & Zhou, Z. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c12156 · Cited by 24
Using GPCRs as Molecular Beacons to Target Ovarian Cancer with Nanomedicines
Khetan, R., Dharmayanti, C., Gillam, T. A., Kübler, E., Klingler‐Hoffmann, M., Ricciardelli, C., Oehler, M. K., Blencowe, A., Garg, S., & Albrecht, H. (2022) · Cancers · doi:10.3390/cancers14102362 · Cited by 24
“NP drug delivery platforms possess advanced properties which drastically increase treatment efficacy [52], and diminish adverse effects [53,54], overcoming many of the limitations of classic chemotherapeutics.”
BackgroundNagano, T., Yasunaga, M., Goto, K., Kenmotsu, H., Koga, Y., Kuroda, J., Nishimura, Y., Sugino, T., Nishiwaki, Y., & Matsumura, Y. (2010) · International Journal of Cancer · doi:10.1002/ijc.25282 · Cited by 24
“These features were comparable to those reported previously.(17,37) The molar ratios of NK012: 5-FU of 1:500 in A549, 1:200 in PC-9 and H520, 1:50 in PC-14, and 1:6,000 in EBC-1 were used for the drug combination studies based on the IC50 values of NK012 and 5-FU (Table 1).”
MethodSelf-citationDuan, S., Cai, S., Xie, Y., Bagby, T. R., Ren, S., & Forrest, M. L. (2012) · Journal of Polymer Science Part A Polymer Chemistry · doi:10.1002/pola.26059 · Cited by 23
Chitosan-based self-assembled nanocarriers coordinated to cisplatin for cancer treatment
Trummer, R., Rangsimawong, W., Sajomsang, W., Kumpugdee-Vollrath, M., Opanasopit, P., & Tonglairoum, P. (2018) · RSC Advances · doi:10.1039/c8ra03069c · Cited by 23
Synthesis and properties of a new micellar polyphosphazene–platinum(II) conjugate drug
Avaji, P. G., Joo, H. I., Park, J. H., Park, K. S., Jun, Y. J., Lee, H. J., & Sohn, Y. S. (2014) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2014.06.014 · Cited by 22
Mao, H. Z., Qian, W., Wang, L., Wu, H. C., Zhou, H., Wang, A., Yang, L. P. H., Chen, H., & Huang, J. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s92722 · Cited by 23
“This is consistent with some previous studies that reported higher toxicity of some lipid-and polymer-formulated CDDP than free CDDP. 12,32,33 The limited amount of CDDP loaded in delivery systems (eg, less than 10 wt%), together with the inevitable deactivation of CDDP during their long-time…”
Noy, J., Chen, F., Akhter, D. T., Houston, Z. H., Fletcher, N. L., Thurecht, K. J., & Stenzel, M. H. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00257 · Cited by 22
Yin, J., Li, Z., Yang, T., Wang, J., Zhang, X., & Zhang, Q. (2010) · Journal of drug targeting · doi:10.3109/10611861003663531 · Cited by 23
“So far, six polymeric micellar formulations are currently in different stages of clinical trials in various countries (Danson et al., 2004; Kim et al., 2004; Matsumura et al., 2004; Hamaguchi et al., 2005; Uchino et al., 2005).”
BackgroundThe Biological Side of Water-Soluble Arene Ruthenium Assemblies
Therrien, B., & Furrer, J. (2014) · Advances in Chemistry · doi:10.1155/2014/589686 · Cited by 22
“Liposomes [22], polymers [23–25], dendrimers [26], organic macrocycles [27], nanoparticles [28], viruses [29], and carbon nanotubes [30, 31] have all shown promises as drug delivery vehicles for platinum therapeutics.”
BackgroundYamashita, K., Tsunoda, S., Gunji, S., Murakami, T., Suzuki, T., Tabata, Y., & Sakai, Y. (2019) · Surgery Today · doi:10.1007/s00595-019-01792-y · Cited by 22
Metallic nanomedicine in cancer immunotherapy
Li, S., Wang, X., Han, H., Xiang, S., Li, M., Long, G., Xia, Y., Zhang, Q., & Li, S. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.017 · Cited by 22
“P(Glu) 6000 , demonstrated a particle size of 28 nm and an impressive drug loading capacity of up to 39% 307 .”
Phillips, M. C., & Mousa, S. A. (2022) · Nanomedicine · doi:10.2217/nnm-2021-0361 · Cited by 24
Recent advancements in Nanotechnology-Mediated Platinum-Based cancer therapy
Itoo, A. M., Ghosh, B., & Biswas, S. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.215796 · Cited by 25
Nanomedicine: pharmacological perspectives
Bhattacharya, S., Alkharfy, K. M., Janardhanan, R., & Mukhopadhyay, D. (2012) · Nanotechnology Reviews · doi:10.1515/ntrev-2011-0010 · Cited by 21
“Introduction of polymeric micelles through the polymer-metal complex formation between polyethylene glycol poly(glutamic acid) block copolymers and cisplatin (NC-6004) signifi cantly enable the nanopolymer-conjugated drug to overcome this challenge many fold [98] .”
BackgroundWang, M., Miura, Y., Tsuchihashi, K., Miyano, K., Nagano, O., Yoshikawa, M., Tanabe, A., Makino, J., Mochida, Y., Nishiyama, N., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.03.038 · Cited by 21
Self-citationPolymer Nanomaterials for Drug Delivery Across the Blood Brain Barrier
Kabanov, A. V., & Batrakova, E. V. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_50 · Cited by 27
Nanotechnology and Pediatric Cancer: Prevention, Diagnosis and Treatment.
Zare‐Zardini, H., Amiri, A., Shanbedi, M., Taheri‐Kafrani, A., Sadri, Z., Ghanizadeh, F., Neámatzadeh, H., Sheikhpour, R., Boroujeni, F. K., Dehshiri, R. M., et al. (2015) · PubMed Central · Cited by 27
Effect of pH on cisplatin encapsulated zeolite nanoparticles: Release mechanism and cytotoxicity
Zakeri, N., Rezaie, H. R., Javadpour, J., & Kharaziha, M. (2021) · Materials Chemistry and Physics · doi:10.1016/j.matchemphys.2021.124964 · Cited by 20
Noncovalent Complexation of Amphotericin-B with Poly(α-glutamic acid)
Mohamed-Ahmed, A. H. A., Les, K. A., Seifert, K., Croft, S. L., & Brocchini, S. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300339p · Cited by 22
Pavan, S. R., & Prabhu, A. (2022) · Journal of Materials Science · doi:10.1007/s10853-022-07649-z · Cited by 21
“The A549 lung cancer cells were exposed 100 lg/ml concentration, which reduced the nephrotoxic effects [61].”
BackgroundBiodegradable polymer–platinum drug conjugates to overcome platinum drug resistance
Yang, Q., Qi, R., Cai, J., Kang, X., Sun, S., Xiao, H., Jing, X., Li, W., & Wang, Z. (2015) · RSC Advances · doi:10.1039/c5ra11297d · Cited by 19
Athanasiou, V., Thimi, P., Liakopoulou, M., Arfara, F., Stavroulaki, D., Kyroglou, I., Skourtis, D., Stavropoulou, I., Christakopoulos, P., Kasimatis, M., et al. (2020) · Polymers · doi:10.3390/polym12122819 · Cited by 19
PEGylated Cisplatin Nanoparticles for Treating Colorectal Cancer in a pH-Responsive Manner
Li, W., Sun, Y., Chen, J., Jiang, Z., & Yang, J. (2022) · Journal of Immunology Research · doi:10.1155/2022/8023915 · Cited by 21
“Uchino et al. used the strategy of cisplatin-incorporating polymeric micelles and reported reduced nephrotoxicity and neurotox-icity while preserving the antitumor activity [42].”
Matsumoto, Y., Miyamoto, Y., Cabral, H., Matsumoto, Y., Nagasaka, K., Nakagawa, S., Yano, T., Maeda, D., Oda, K., Kawana, K., et al. (2016) · Cancer Science · doi:10.1111/cas.12926 · Cited by 18
Self-citationLoghmani, M. H., Shojaie, A. F., & Hosseini, S. A. (2020) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2020.12.018 · Cited by 18
Manganese graft ionomer complexes (MaGICs) for dual imaging and chemotherapy
Pothayee, N., Pothayee, N., Hu, N., Zhang, R., Kelly, D. F., Koretsky, A. P., & Riffle, J. S. (2014) · Journal of Materials Chemistry B · doi:10.1039/c3tb21299h · Cited by 20
Platinum in Biomedical Applications
Sinitsyna, O. V., Paralikar, P., Pandit, R., & Rai, M. K. (2018) · Springer eBooks · doi:10.1007/978-3-319-74814-6_7 · Cited by 22
Platinum Drug‐Incorporating Polymeric Nanosystems for Precise Cancer Therapy
Liu, W., Li, X., Wang, T., Xiong, F., Sun, C., Yao, X., & Huang, W. (2023) · Small · doi:10.1002/smll.202208241 · Cited by 18
cRGD targeted and charge conversion-controlled release micelles for doxorubicin delivery
Guan, X., Hu, X., Li, Z., Zhang, H., & Xie, Z. (2015) · RSC Advances · doi:10.1039/c4ra14368j · Cited by 19
Salakhieva, D. V., Shevchenko, V. D., Németh, C., Gyarmati, B., Szilágyi, A., & Abdullin, T. I. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.12.007 · Cited by 17
Zhang, J., & Ma, P. X. (2009) · Angewandte Chemie · doi:10.1002/ange.200804135 · Cited by 17
Nanoparticle-based Cisplatin Therapy for Cancer
Babu, A., Amreddy, N., & Ramesh, R. (2015) · Therapeutic Delivery · doi:10.4155/tde.14.109 · Cited by 18
Mirhadi, E., Gheybi, F., Mahmoudi, N., Hemmati, M., Soleymanian, F., Ghasemi, A., Askarizadeh, A., Iranshahi, M., Jaafari, M. R., & Alavizadeh, S. H. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121946 · Cited by 16
Merino, J. J., Durán, A. G., Chinchilla, N., & Macías, F. A. (2025) · Phytochemistry Reviews · doi:10.1007/s11101-025-10089-7 · Cited by 18
“Emodin has been found to act as a chemical sensitizer, enhancing the antitumor effects of cisplatin (Uchino et al. 2005), and similarly, it can boost the antitumor effects of paclitaxel in both in vivo and in vitro settings (Peng et al. 2021).”
Use of Nanostructured Polymer in the Delivery of Drugs for Cancer Therapy
Khan, M. J., Svedberg, A., Singh, A. A., Ansari, M. S., & Karim, Z. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816771-7.00013-2 · Cited by 21
Soo, P. L., Dunne, M., Liu, J., & Allen, C. J. (2008) · Springer eBooks · doi:10.1007/978-0-387-77668-2_12 · Cited by 17
Wang, H., Deng, H. X., Gao, M., Zhang, Y., Liu, R., Hou, W., Xu, H., & Zhang, W. (2023) · ACS Materials Letters · doi:10.1021/acsmaterialslett.3c00747 · Cited by 15
Nanovector-based therapies in advanced pancreatic cancer.
Tsai, C.-S., Park, J. W., & Chen, L. (2011) · PubMed Central · doi:10.3978/j.issn.2078-6891.2011.034 · Cited by 16
“In animal study, NC-6004 showed characteristic delayed total body clearance and higher area-under cur ve as compared with free cisplatin with a ratio of 1/19 and 65 folds, respectively (42).”
BackgroundYoshii, N., Fujimoto, K., & Okazaki, S. (2015) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2015.12.062 · Cited by 15
Zhuang, W., Ma, B., Liu, G., Chen, X., & Wang, Y. (2017) · Regenerative Biomaterials · doi:10.1093/rb/rbx012 · Cited by 15
Brustolin, L., Pettenuzzo, N., Nardon, C., Quarta, S., Montagner, I. M., Pontisso, P., Rosato, A., Conte, P., Merigliano, S., & Fregona, D. (2020) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2020.111259 · Cited by 14
Improvement of Kiteplatin Efficacy by a Benzoato Pt(IV) Prodrug Suitable for Oral Administration
Barbanente, A., Gandin, V., Ceresa, C., Marzano, C., Ditaranto, N., Hoeschele, J. D., Natile, G., Arnesano, F., Pacifico, C., Intini, F. P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137081 · Cited by 15
“the drug induces side effects [7,8] such as nausea, vomiting, myelosuppresion, immunosuppression, nephrotoxicity, neurotoxicity, and hearing loss.”
BackgroundOumzil, K., Khiati, S., Camplo, M., Koquely, M., Chuttani, K., Chaturvedi, S., Mishra, A. K., & Barthélémy, P. (2014) · New Journal of Chemistry · doi:10.1039/c4nj00559g · Cited by 14
Aliabadi, H. M., Elhasi, S., Brocks, D. R., & Lavasanifar, A. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21036 · Cited by 14
Uchegbu, I. F., Lalatsa, A., & Wong, D. (2013) · Springer eBooks · doi:10.1007/978-1-4614-9164-4_9 · Cited by 14
Novel Organic and Inorganic Nanoparticles as a Targeted Drug Delivery Vehicle in Cancer Treatment
Muthukrishnan, S., Anand, A. V., Palanisamy, K., Gunasangkaran, G., Ravi, A. K., & Balasubramanian, B. (2022) · Nanotechnology in the life sciences · doi:10.1007/978-3-030-80371-1_4 · Cited by 16
Polymeric dinulcear platinum(ii) complex micelles for enhanced antitumor activity
Wang, R., Hu, X., Xiao, H., Xie, Z., Huang, Y., & Jing, X. (2012) · Journal of Materials Chemistry B · doi:10.1039/c2tb00240j · Cited by 13
Voon, S. H., Kue, C. S., Imae, T., Saw, W. S., Lee, H. B., Kiew, L. V., Chung, L. Y., & Yusa, S. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.10.023 · Cited by 13
“…2006), paclitaxel (PTX)-encapsulated PEG-polyaspartate block copolymer micelle (NK105) in phase II (Hamaguchi et al., 2005; Matsumura and Kataoka, 2009), and cisplatinincorporated PEG-polyglutamate block copolymer micelle (NC-6004) in phase II (Matsumura and Kataoka, 2009; Uchino et al., 2005).”
BackgroundMartey, O., Nimick, M., Taurin, S., Sundararajan, V., Greish, K. F., & Rosengren, R. J. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s148908 · Cited by 13
“48 Importantly, this was not an issue in this study as the subchronic administration of SMA-RL71 also showed that the nanoformulation was nontoxic to the mice as plasma indicators of liver and kidney function were in the normal range and were not different to untreated control.”
Peripheral neurotoxic effects of cisplatin on rats and treatment with rutin
Yaşar, H., Ersoy, A., Çimen, F. K., Mammadov, R., Kurt, N., & Arslan, Y. K. (2019) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/111819 · Cited by 13
Ligand-installed polymeric nanocarriers for combination chemotherapy of EGFR-positive ovarian cancer
Xi, X., Lei, F., Gao, K., Li, J., Liu, R., Karpf, A. R., & Bronich, T. K. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.033 · Cited by 12
Multifunctional core–shell polymeric and hybrid nanoparticles as anticancer nanomedicines
Goračinova, K., Geškovski, N., Dimchevska, S., Li, X., & Gref, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813669-0.00004-x · Cited by 12
Ashihara, K., Terai, Y., Tanaka, T., Tanaka, Y., Fujiwara, S., Maeda, K., Tunetoh, S., Sasaki, H., Hayashi, M., & Ohmichi, M. (2020) · Oncology Letters · doi:10.3892/ol.2020.11279 · Cited by 12
“Moreover, new therapies such as drug delivery systems (DDS) also indicate more effective therapies into solid tumors while lessening their distribution into normal, healthy tissue (8).”
BackgroundNovel Kiteplatin Pyrophosphate Derivatives with Improved Efficacy
Curci, A., Gandin, V., Marzano, C., Hoeschele, J. D., Natile, G., & Margiotta, N. (2017) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.7b00931 · Cited by 12
Cisplatin‐Rich Polyoxazoline–Poly(aspartic acid) Supramolecular Nanoparticles
Zhang, P., Yuan, K., Li, C., Zhang, X., Wu, W., & Jiang, X. (2017) · Macromolecular Bioscience · doi:10.1002/mabi.201700206 · Cited by 12
Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma
Hsueh, C.-T., Selim, J. H., Tsai, J. Y., & Hsueh, C.-T. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i31.7080 · Cited by 11
Anti-Aβ-scFv-loaded polymeric nano-micelles with enhanced plasma stability
Sotoudegan, F., Sotoudegan, F., Talebkhan, Y., Afshar, S. H., Barkhordari, F., & Davami, F. (2021) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgaa068 · Cited by 11
Song, J., Xu, T., Zhang, Y., Guo, H., Ren, W., Zhu, S., & Yang, L. (2016) · Drug Delivery · doi:10.3109/10717544.2016.1172369 · Cited by 11
“For example, Uchino et al. (2005) chelated CDDP positively charged platinum species to carboxylate-rich copolymers with a drug loading of 30 wt.%.”
BackgroundPatil, B. R., Kang, S. Y., Jung, D., Avaji, P. G., Jun, Y. J., Lee, H. J., & Sohn, Y. S. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s235618 · Cited by 11
Dong, S., Tang, Y., He, P., Ma, S., Song, W., Deng, M., & Tang, Z. (2021) · Polymer International · doi:10.1002/pi.6342 · Cited by 12
Polymeric Prodrugs Containing Metal-Based Anticancer Drugs
Aderibigbe, B. A. (2015) · Journal of Inorganic and Organometallic Polymers and Materials · doi:10.1007/s10904-015-0220-7 · Cited by 11
Advances in Polymer Micelles for Cancer Therapy: From Conventional to Smart Delivery Systems
Bryaskova, R. G., Staykov, K., & Ganchev, D. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18020177 · Cited by 11
Zhang, Z., Yan, W., & Ji, Y. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb01659a · Cited by 10
Mektrirat, R., Paengjun, N., Chongrattanameteekul, P., Umsumarng, S., Cheunsri, S., Photichai, K., Lewchalermvong, K., Sansamur, C., Okonogi, S., & Katip, W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1282464 · Cited by 10
Mostaghimi, H., Mehdizadeh, A., Jahanbakhsh, M., Dehghanian, A., & Askari, R. (2017) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1224_16 · Cited by 10
He, L., Ye, S., Fang, J. Y., Zhang, Y., Cui, C., Wang, A., Zhao, Y., & Shi, H. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c02793 · Cited by 10
Metadata
- Authors
- Uchino, H., Matsumura, Y., Negishi, T., Koizumi, F., Hayashi, T., Honda, T., Nishiyama, N., Kataoka, K., Naito, S., & Kakizoe, T.
- Affiliations
- National Cancer Center Hospital East (JP)
- NanoCarrier (Japan) (JP)
- Fukushima Medical University (JP)
- The University of Tokyo (JP)
- Kyushu University (JP)
- National Cancer Centre Japan (JP)
- Corresponding author
- Matsumura, Y
- Venue
- British Journal of Cancer
- Published
- 2005-09
- Volume
- 93
- Issue
- 6
- Pages
- 678-687
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2361620
- OpenAlex
- W1974920077
- Cited by
- 430
- References
- 37
- Citations by year
- 2026: 10 · 2025: 7 · 2024: 9 · 2023: 12 · 2022: 20 · 2021: 22 · 2020: 21 · 2019: 20 · 2018: 9 · 2017: 34 · 2016: 27 · 2015: 35 · 2014: 39 · 2013: 32 · 2012: 29
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Ministry of Health, Labour and Welfare
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Chemotherapy-induced organ toxicity mitigation
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- cisplatin, polymeric micelles, nephrotoxicity, neurotoxicity, hepatotoxicity, sensory nerve conduction velocity, antitumour activity, pharmacokinetics, drug toxicity reduction
- MeSH terms
- Animals, Antineoplastic Agents, Body Weight, Brain, Cisplatin, Drug Carriers, Female, Humans, Kidney, Kidney Diseases, Liver, Mice, Inbred BALB C, Mice, Nude, Micelles, Polyethylene Glycols, Tumor Cells, Cultured, Rats, Sprague-Dawley, Neurotoxicity Syndromes, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.